CSL Behring announces the closing of its global commercialization and license agreement for an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of Hemophilia B from uniQure, a leading gene therapy company.
The therapie has the potential to be the first-ever gene therapy approved for Hemophilia B and to help CSL Behring deliver on our ongoing commitment to improving the lives of those living with Hemophilia B.
Agreement with uniQure on Hemophilia B gene therapy
CSL closes commercialization and license agreement for Hemophilia B gene therapy.
